Current status: Answered by Angela Constance on 1 September 2026
To ask the Scottish Government what estimate it has made of the annual cost of providing semaglutide (Wegovy) and tirzepatide (Mounjaro) treatment for reducing weight in adults under the approved NHS Scotland Patient Access Scheme, and over what timescale it expects all eligible patients to be able to access treatment.
In Scotland, Patient Access Schemes (PAS) offering discounts by pharmaceutical companies to list prices of medicines are considered by the Patient Access Scheme Advisory Group (PASAG) and are commercial-in-confidence. Therefore this information is not held centrally.
The Scottish Government published a national consensus statement in September 2024, to support Health Boards to consider how best to implement these weight loss medicines. It is a matter for individual Health Boards to consider the implementation of any new medicine within their services in order to meet the needs of their local population in a safe and clinically appropriate way. This includes determining which criteria they apply in prescribing obesity medicines to individuals, and for taking appropriate phased steps to make them available across their services.